{"id":5957,"date":"2019-09-17T13:21:32","date_gmt":"2019-09-17T07:51:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5957"},"modified":"2023-02-10T11:58:10","modified_gmt":"2023-02-10T06:28:10","slug":"recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","title":{"rendered":"AlivaMab collaborates with Janssen for antibody discovery; Lundbeck acquires Alder BioPharmaceutical; Helsinn and Mundipharma announce China approval of Akynzeo"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>AlivaMab Discovery Services (ADS) has announced an antibody discovery\nagreement against multiple targets with Janssen Research &amp; Developments. <\/strong><\/h4>\n\n\n\n<p><strong>AlivaMab<\/strong>, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and R&amp;D capabilities to Janssen. ADS will use its Mouse platform which is already widely used by its own Research team to produce antibodies against multiple targets for Janssen to evaluate. <\/p>\n\n\n\n<p>The AlivaMab Mouse has been\nlicensed to eight of the top 15 pharmaceutical companies, along with the\nseveral other public and private companies. <\/p>\n\n\n\n<p>The financial terms of the deal\nhave not been unveiled yet. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Lundbeck has entered into an agreement to purchase Alder BioPharmaceuticals\nfor almost USD 2 Billion. <\/strong><\/h4>\n\n\n\n<p>Lundbeck is a global\npharmaceutical firm developing and advancing the pipeline for brain diseases. The\ncompany\u2019s products are targeted at the disease areas within psychiatry and\nneurology. For moving forward to realize its aim, Lundbeck is buying Alder\nBioPharmaceuticals, a clinical-stage biopharmaceutical company transforming\nmigraine treatment.<\/p>\n\n\n\n<p>The buyout will let Alder have an upfront offer of USD 18.00 per share in cash, along with one non-tradeable Contingent Value Right (CVR), authorizing it to have an additional USD 2.00 per share upon approval of <strong>eptinezumab <\/strong>by the European Medicines Agency (EMA). <\/p>\n\n\n\n<p>The transaction is valued at up\nto USD 1.95 billion, net of cash. <\/p>\n\n\n\n<p>According to the Migraine Trust\nOrganization, globally Migraine is considered the 7th most disabling disease among\nall diseases (responsible for 2.9% of all years of life lost to\ndisability\/YLDs) and the leading cause of disability among all neurological\ndisorders.<\/p>\n\n\n\n<p>Many medications are available to\ntreat migraine and the choice depends on the severity and frequency of headaches.<\/p>\n\n\n\n<p>After the approval of Erenumab and Fremanezumab, several more studies are needed to fully understand the clinical potential, long-term safety, and cost-effectiveness of these therapies. Key players, such as Axsome Therapeutics, IMPAX Laboratories, Inc., Impel NeuroPharma, Zosano Pharma Corporation, Biohaven Pharmaceuticals, Inc., Allergan, and many others are involved in developing therapies for Migraine. <br>Expected launch of emerging therapies, such as <strong>INP104<\/strong> (Impel NeuroPharma), <strong>AXS-07<\/strong> (Axsome Therapeutics), <strong>M207\/ADAM<\/strong> <strong>Zolmitriptan <\/strong>(Zosano Pharma Corporation), <strong>Rimegepant <\/strong>(Biohaven Pharmaceuticals), Ubrogepant (Allergen), etc. are expected to create a noticeable increase in the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market\">Migraine market size<\/a><\/strong> in the upcoming years.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Helsinn and Mundipharma China Pharmaceutical recently have received the\nNational Medical Products Administration\u2019s approval of the oral formulation of Akynzeo\nin China. <\/strong><\/h4>\n\n\n\n<p>The FDA recommended the use of <strong>Akynzeo IV<\/strong> (netupitant\/pelonosetron) in combination with dexamethasone in adults for the treatment of chemotherapy-induced nausea and vomiting (CINV). <\/p>\n\n\n\n<p>Under the terms of the agreement, Mundipharma China Pharmaceutical will have exclusive marketing, promotion and sale rights and Helsinn will undertake the task of supplying the drug to Mundipharma. Also, the latter will be involved in co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities.<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-nausea-and-vomiting-pipeline-insight\">Chemotherapy-Induced Nausea and Vomiting<\/a><\/strong> is one of the most distressing adverse effects of chemotherapy, and a primary factor for the discontinuation of the chemotherapy cycles leading to poor patient compliance.<\/p>\n\n\n\n<p>The expected launch of other emerging therapies such as APD403 (Acacia Pharma) will change the treatment landscape of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-nausea-and-vomiting-market\">Chemotherapy-Induced Nausea and Vomiting<\/a><\/strong> during the forecast period [2019-2028].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AlivaMab Discovery Services (ADS) has announced an antibody discovery agreement against multiple targets with Janssen Research &amp; Developments. AlivaMab, a pharmaceutical providing fully human therapeutic antibody discovery services, will render its therapeutic antibody candidates, its clinical expertise and R&amp;D capabilities to Janssen. ADS will use its Mouse platform which is already widely used by its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[349,639,5789],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-latest-pharma-news","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | AlivaMab, Lundbeck, Helsinn, Mundipharma<\/title>\n<meta name=\"description\" content=\"Helsinn and Mundipharma China Pharmaceutical recently have received the NMPA\u2019s approval of the oral formulation of Akynzeo in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | AlivaMab, Lundbeck, Helsinn, Mundipharma\" \/>\n<meta property=\"og:description\" content=\"Helsinn and Mundipharma China Pharmaceutical recently have received the NMPA\u2019s approval of the oral formulation of Akynzeo in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-17T07:51:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:28:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | AlivaMab, Lundbeck, Helsinn, Mundipharma","description":"Helsinn and Mundipharma China Pharmaceutical recently have received the NMPA\u2019s approval of the oral formulation of Akynzeo in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","og_locale":"en_US","og_type":"article","og_title":"Pharma News | AlivaMab, Lundbeck, Helsinn, Mundipharma","og_description":"Helsinn and Mundipharma China Pharmaceutical recently have received the NMPA\u2019s approval of the oral formulation of Akynzeo in China.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-09-17T07:51:32+00:00","article_modified_time":"2023-02-10T06:28:10+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma","name":"Pharma News | AlivaMab, Lundbeck, Helsinn, Mundipharma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1.png","datePublished":"2019-09-17T07:51:32+00:00","dateModified":"2023-02-10T06:28:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Helsinn and Mundipharma China Pharmaceutical recently have received the NMPA\u2019s approval of the oral formulation of Akynzeo in China.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-alivamab-janssen-alder-lundbeck-helsinn-mundipharma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1.png","width":772,"height":482,"caption":"Pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/17140407\/breaking-news-1-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Sep 17, 2019","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Sep 17, 2019 1:21 pm","modified":"Updated on Feb 10, 2023 11:58 am"},"featured_img_caption":"Pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5957"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5961"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5957"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5957"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}